Boehringer offers selected pre-clinical molecules to scientists worldwide for free via new platform
Boehringer Ingelheim has recently unveiled opnME.com, a centralised platform that allows access to selected pre-clinical molecules from its portfolio for free for non-clinical investigation by international scientists.
The German pharmaceutical company hopes that the move will stimulate independent drug discovery and collaborative partnerships worldwide, in addition to the identification of novel treatment solutions for patients.
The available molecules are divided into two distinct groups. For now the molecules are offered via a simple shopping cart system and do not require any specific intellectual property discussion. For the remaining molecules, a crowdsourcing option is available which is designed to facilitate collaboration between scientists. These molecules require a research proposal to be submitted, and if successful, the chosen candidate will work with Boehringer scientists on research and development on the project.
“Working together with scientists across the world, we can accelerate research in a wide range of biomedical research areas,” explained Dr Clive R Wood, Senior Corporate Vice President, Discovery Research at Boehringer Ingelheim. “This exciting new initiative further expands Boehringer Ingelheim’s global external innovation footprint and will help unlock the full potential of some of our most interesting compounds. By sharing these compounds with scientists around the world, we will advance scientific research and expect to spark discoveries that will lead to safe and effective new medicines for patients.”
opnME.com represents another of Boehringer’s initiatives to drive research and collaboration in the industry, joining the likes of the company’s Research Beyond Borders and the Boehringer Ingelheim Venture Fund initiatives.
Wood added: “I invite interested scientists worldwide to visit opnMe.com to access our molecules. We will measure the success of this initiative in terms of new experiments, publications and relationships forged. This approach to open innovation reflects our determination to break down barriers to the advancement of biomedical research and bring breakthrough medicines to patients”